Save up -80% on Elosulfase alfa
Note: this is a drug discount program, not an insurance plan.
2018 Price of Elosulfase alfa
* price without discount in nearest pharmacy. Price may vary.
We offer free Elosulfase alfa coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your discount card in most local pharmacies to get a discount on Elosulfase alfa every time. What are you waiting for? Claim your prescription drug card now!
Elosulfase alfa volume of distribution
396 mL/kg, standard deviation 316.
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Elosulfase alfa
Elosulfase alfa is a synthetic version of the enzyme N-acetylgalactosamine-6-sulfatase. It was approved by the FDA in 2014 for the treatment of Morquio syndrome. Elosulfase alfa was developed by BioMarin Pharmaceutical Inc. and is marketed under the brand Vimizim . The recommended dose is 2 mg per kg given intravenously over a minimum range of 3.5 to 4.5 hours, based on infusion volume, once every week.
Elosulfase alfa mechanism of action
Mucopolysaccharidoses comprise a group of lysosomal storage disorders caused by the deficiency of specific lysosomal enzymes required for the catabolism of glycosaminoglycans (GAG). Mucopolysaccharidosis IVA (MPS IVA, Morquio A Syndrome) is characterized by the absence or marked reduction in N-acetylgalactosamine-6-sulfatase activity. The sulfatase activity deficiency results in the accumulation of the GAG substrates, KS and C6S, in the lysosomal compartment of cells throughout the body. The accumulation leads to widespread cellular, tissue, and organ dysfunction. Vimizim is intended to provide the exogenous enzyme N-acetylgalactosamine-6-sulfatase that will be taken up into the lysosomes and increase the catabolism of the GAGs KS and C6S. Elosulfase alfa uptake by cells into lysosomes is mediated by the binding of mannose-6-phosphate-terminated oligosaccharide chains of elosulfase alfa to mannose-6-phosphate receptors. In the absence of an animal disease model that recapitulates the human disease phenotype, elosulfase alfa pharmacological activity was evaluated using human primary chondrocytes from two MPS IVA patients. Treatment of MPS IVA chondrocytes with elosulfase alfa induced clearance of KS lysosomal storage from the chondrocytes.
Dosage forms of Elosulfase alfa
|Injection, solution, concentrate||intravenous||5 mg/5mL|
Biomarin International Limited
Humans and other mammals
Indication of Elosulfase alfa
Vimizim is a hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome).
Toxicity of Elosulfase alfa
RX24 Drugs Disclaimer: before buying a Elosulfase alfa on prescription, consult your healthcare provider. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.